AI Workflow for Continuous Safety Monitoring in Adaptive and Decentralized Clinical Trials

Manual review of ePRO, wearables, and site data creates a 2-4 week lag in identifying potential safety issues. A custom workflow ingests and fuses these streams in real-time, applying adaptive signal detection algorithms to flag anomalies as they emerge. This compresses the detection timeline from weeks to days, allowing the Data Monitoring Committee (DMC) to review potential risks before they escalate, protecting patient safety and trial integrity.

Decentralized trials generate fragmented data from wearables (e.g., heart rate, activity), ePRO diaries, and remote site visits. Safety associates spend hours daily collating and normalizing this data for review. An automated orchestration layer, built with LangGraph or similar, continuously ingests via FHIR/HL7 APIs, normalizes timestamps and units, and presents unified patient timelines. This eliminates repetitive aggregation work, freeing medical staff for higher-value causality assessment.

Late identification of safety trends often leads to reactive protocol amendments—a process that can cost $500k+ and delay trials by months. A continuous monitoring workflow provides the DMC with near-real-time dashboards of safety metrics against pre-defined stopping rules. This enables data-driven decisions to adjust dosing, refine inclusion criteria, or pause enrollment proactively, preserving trial viability and avoiding the high cost and timeline impact of major amendments.

Manual processes introduce inconsistencies in adverse event coding (MedDRA) and narrative documentation, creating rework during audit or submission. The workflow embeds automated agents for MedDRA coding suggestion and narrative drafting from structured data flows. This ensures standardized, audit-ready outputs from day one, reducing QC cycles and accelerating the assembly of integrated safety summaries for FDA/EMA submissions.

Traditional safety systems cannot support the dynamic data flows and decision logic of adaptive trials. A custom architecture creates a closed-loop control system: signal detection agents trigger alerts, which are routed through configurable approval gates (e.g., to the DMC chair). Approved adaptation decisions (like a dose change) are then programmatically pushed to the EDC (e.g., Medidata Rave) and trial management systems. This turns the safety function from a passive monitor into an active orchestrator of trial evolution.

A major safety incident in a late-phase trial can wipe billions from market cap and derail development programs. Continuous monitoring provides an early-warning system, increasing the probability of catching issues early when interventions are more effective. The workflow includes robust audit trails, explanation layers for AI suggestions, and mandatory human review gates for critical signals. This demonstrable vigilance strengthens regulatory trust and protects the asset's long-term value.

This agent orchestrates the real-time ingestion and harmonization of disparate data streams: wearable sensor telemetry, ePRO/eCOA submissions, central lab results, and site EDC updates. It handles protocol-specific data mappings, applies quality checks for missing or implausible values, and outputs a normalized, time-series patient profile. This eliminates the manual data reconciliation that delays signal detection by days.

A stateful agent that runs continuous statistical process control and machine learning anomaly detection on the normalized patient cohort. It compares individual trajectories against pre-defined safety boundaries and historical control arms, flagging deviations (e.g., sustained tachycardia, liver enzyme spikes). Each signal is assigned a severity score and initial causality assessment (related/unrelated to investigational product) for routing.

The core workflow controller, built on a framework like LangGraph, manages state and executes business logic. It evaluates triaged signals against the trial's adaptive protocol rules. For critical signals, it automatically drafts alert packages for the Data Monitoring Committee (DMC), including patient-level data and aggregate trends. It also triggers protocol-defined actions, such as pausing enrollment for a specific cohort or updating site guidance.

For signals confirmed as reportable adverse events, this agent initiates expedited reporting workflows. It auto-populates an ICSR (Individual Case Safety Report) draft by retrieving all relevant patient data from the trial's EDC and the normalized profile. It suggests MedDRA coding and generates a preliminary narrative, creating a structured case file ready for medical review and submission to health authorities and cross-functional partners.

A mandatory governance component that logs every agent decision, data point accessed, and logic path taken. It generates a human-readable explanation for each signal alert and protocol action, citing the specific data thresholds and rules triggered. This creates a defensible audit trail for regulatory inspection and DMC review, ensuring the AI-driven workflow operates with transparency and within predefined statistical boundaries.

The underlying architecture that connects agents to enterprise systems. It uses secure APIs and message queues to interface with Clinical Trial Management Systems (CTMS like Veeva) and Electronic Data Capture (EDC like Medidata Rave). Deployment is typically containerized (e.g., Kubernetes) for scalability across trial phases, with feature flags allowing gradual rollout of monitoring logic to specific trial arms or sites to manage risk.